Page 8 - OHKF_Biotech_EN
P. 8
Executive summary its branding advantage will be leveraged to introduce Hong Kong- the two cities, including the GBA sub-centres for drug and medical
style management into the Mainland to meet international
device evaluation and inspection established by the National
Medical Products Administration in the Shenzhen park, and the
standards. For the production stage, we recommend that
subsidiaries of the National Intellectual Property Administration
production lines for cutting-edge products and pilot batches be
and the Human Genetic Resources Administration of China,
set up in the Loop. For the product launch stage, as new drug
approval standards in the Mainland are increasingly in line with
in the Loop. Second, the platform can interface with research
international standards, particularly with marked improvement in Ministry of Science and Technology that we propose to be set up
the quality of clinical trial data, Hong Kong’s Department of Health project funds set up by the two governments, venture capital
should consider adding mainland China into its designated list, so funds, research institutes and collaboration opportunities, as well
that new drugs that are launched in any two places on the list will as professional services such as intellectual property services.
be recognised in Hong Kong; in the long run, Hong Kong can Finally, the platform can attract Contract Research Organisations
attract and train talent in drug approval and explore the (CRO) and Contract Development and Manufacturing
development of an independent new drug approval mechanism. Organisations (CDMO) to share some of their R&D procedures
Likewise, the Shenzhen government should seek approval from with biomedical companies, thereby enhancing the clinical trial
the Health Commission of Guangdong Province to relax relevant capabilities and quality control standards of
requirements and allow the use of efficacy data of drugs and healthcare organisations.
medical devices, which have already been approved in Hong
Kong, on Shenzhen patients for further registration in the Recommendation 4 Encouraging
Mainland. This will expedite the overall approval process. knowledge transfer in tertiary institutions and
nurturing multi-skilled talent well-versed
Recommendation 3 Establishing in biotech and business
a one-stop service platform in the Loop to
provide professional support services While the Regulation of Shenzhen Special Economic Zone on
Scientific and Technological Innovation contains a number of
To better leverage the Loop to help Mainland enterprises expand measures aimed at encouraging knowledge transfer, Hong Kong
into international markets and Hong Kong enterprises access the has a lot to catch up on. To prevent researchers and enterprises
Mainland market, we recommend the joint establishment of a from flowing one way and congregating into a particular park in the
one-stop service platform in the Loop by the Hong Kong- Loop, and to more efficiently transfer world-class research outcomes
Shenzhen Innovation and Technology Park Limited and the Futian into the industry, we propose the following recommendations:
district government to provide biotechnology transfer services. 1) the University Grants Committee of Hong Kong should establish
First, such a platform can liaise with the competent regulators of an assessment framework for knowledge transfer in tertiary institutions
6